Safety and Efficacy of Ashwagandha Root Extract on Cognition, Energy and Mood Problems in Adults: Prospective, Randomized, Placebo-Controlled Study.

IF 2.1 4区 医学 Q2 PSYCHOLOGY, CLINICAL Journal of psychoactive drugs Pub Date : 2024-11-05 DOI:10.1080/02791072.2024.2424279
Sanjiv Kale, Adrian Lopresti, Ravleen Suri, Neha Garg, Deepak Langade
{"title":"Safety and Efficacy of Ashwagandha Root Extract on Cognition, Energy and Mood Problems in Adults: Prospective, Randomized, Placebo-Controlled Study.","authors":"Sanjiv Kale, Adrian Lopresti, Ravleen Suri, Neha Garg, Deepak Langade","doi":"10.1080/02791072.2024.2424279","DOIUrl":null,"url":null,"abstract":"<p><p>This prospective, randomized, placebo-controlled study assessed the effects of Ashwagandha root extract (ARE) on cognition, energy, and mood in adults with self-reported cognitive and energy problems. Healthy subjects aged 30-75 years were randomized to receive ashwagandha (<i>Withania somnifera</i>) root extract (ARE) 600 mg/day (<i>n</i> = 60)/identical placebo (<i>n</i> = 60) orally for 8 weeks. Cognitive function was assessed at baseline and week 8 using a Computerized Mental Performance Assessment System (COMPASS). Secondary outcomes were Profile of Mood States Abbreviated Version (POMS-A), Mental Fatigue Scale (MFS) and Behavior Rating Inventory of Executive Function-Adult (BRIEF-A) for effects on mood, mental fatigue and executive function, respectively, assessed at baseline, week 4 and 8. Greater improvement (<i>p</i> < .05) from baseline scores were seen with ARE as against placebo for COMPASS items episodic memory, working memory and accuracy of attention. ARE also improved the POMS-A, MFS and BRIEF-A scores from baseline suggesting an improvement in mood, vigor, and an increase in the executive functioning respectively with ARE. The herb was well tolerated and had a good patient compliance with no serious adverse events reported in either of the groups. This study suggests that a dose of 600 mg a day can improve cognition, energy, and mood in adults with self-reported cognitive and energy problems.</p>","PeriodicalId":16902,"journal":{"name":"Journal of psychoactive drugs","volume":" ","pages":"1-13"},"PeriodicalIF":2.1000,"publicationDate":"2024-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of psychoactive drugs","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/02791072.2024.2424279","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PSYCHOLOGY, CLINICAL","Score":null,"Total":0}
引用次数: 0

Abstract

This prospective, randomized, placebo-controlled study assessed the effects of Ashwagandha root extract (ARE) on cognition, energy, and mood in adults with self-reported cognitive and energy problems. Healthy subjects aged 30-75 years were randomized to receive ashwagandha (Withania somnifera) root extract (ARE) 600 mg/day (n = 60)/identical placebo (n = 60) orally for 8 weeks. Cognitive function was assessed at baseline and week 8 using a Computerized Mental Performance Assessment System (COMPASS). Secondary outcomes were Profile of Mood States Abbreviated Version (POMS-A), Mental Fatigue Scale (MFS) and Behavior Rating Inventory of Executive Function-Adult (BRIEF-A) for effects on mood, mental fatigue and executive function, respectively, assessed at baseline, week 4 and 8. Greater improvement (p < .05) from baseline scores were seen with ARE as against placebo for COMPASS items episodic memory, working memory and accuracy of attention. ARE also improved the POMS-A, MFS and BRIEF-A scores from baseline suggesting an improvement in mood, vigor, and an increase in the executive functioning respectively with ARE. The herb was well tolerated and had a good patient compliance with no serious adverse events reported in either of the groups. This study suggests that a dose of 600 mg a day can improve cognition, energy, and mood in adults with self-reported cognitive and energy problems.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
芦根提取物对成人认知、能量和情绪问题的安全性和有效性:前瞻性、随机、安慰剂对照研究。
这项前瞻性、随机、安慰剂对照研究评估了芦根提取物(ARE)对自我报告有认知和精力问题的成年人的认知、精力和情绪的影响。年龄在 30-75 岁之间的健康受试者随机接受芦根提取物(ARE)600 毫克/天(n = 60)/同种安慰剂(n = 60)口服,为期 8 周。认知功能在基线和第 8 周使用计算机化智力表现评估系统 (COMPASS) 进行评估。次要结果为情绪状态简易版(POMS-A)、精神疲劳量表(MFS)和执行功能行为评定量表-成人(BRIEF-A),分别用于评估在基线、第 4 周和第 8 周对情绪、精神疲劳和执行功能的影响。改善幅度更大(p
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
5.30
自引率
7.10%
发文量
62
期刊最新文献
Associations Between Ayahuasca Use in Naturalistic Settings and Mental Health and Wellbeing Outcomes: Analysis of a Large Global Dataset. Factors Associated with Psychosis in 2098 Methamphetamine Users Admitted to 104 Outpatient Counseling Centers in 80 Cities in Turkey. Maintenance Intramuscular Ketamine-Assisted Psychotherapy, a Retrospective Chart Review of Efficacy, Adverse Events, and Dropouts from a Community Practice. Highs and Lows: A Mixed-Methods Analysis of the Impact of Adult Use Legalization on Medical Cannabis Patients. 24-Hour Induction of Transdermal Buprenorphine to Buprenorphine Extended-Release.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1